The manufacturer of nadolol (Corgard®) has confirmed that this product has been discontinued. The product has been discontinued for commercial reasons.
Nadolol, a beta blocker, is licensed for use in hypertension, angina, arrhythmias, migraine prophylaxis and adjunctive treatment of thyrotoxicosis. Supply chain stock will be limited and there is no generic alternative. Treatment should not be stopped abruptly and therefore patients who are currently being prescribed nadolol should be identified, reviewed offered an appropriate alternative.
Action: Clinicians should be aware of this product being discontinued. It would be prudent to run clinical system searches to identify any patients who are currently prescribed this product to allow a review and an alternative to be arranged.
Update: As of June 2018 it would seem that the manufacturer reversed the decision to discontinue Corgard® and the 80mg tablets remain available and in the supply chain.
|« SMC Update - April 2016||FDA safety concerns over saxagliptin and alogliptin »|